Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

RESCULA

UNOPROSTONE ISOPROPYL

Standard Dose
0.15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview RESCULA is listed in Drugs@FDA under application 021214 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient UNOPROSTONE ISOPROPYL Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SUCAMPO PHARMA LLC Submission history Latest submission status date: 2014-07-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview RESCULA is listed in Drugs@FDA under application 021214 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient UNOPROSTONE ISOPROPYL Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SUCAMPO PHARMA LLC Submission history Latest submission status date: 2014-07-10 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
RESCULA (UNOPROSTONE ISOPROPYL) | Drug Monograph | MedicHelpline